Hjem › Kronisk lymfatisk leukemi › California › Los Angeles
Kliniske studier for Kronisk lymfatisk leukemi i Los Angeles, CA
8 studier for Kronisk lymfatisk leukemi søker deltakere på steder i og rundt Los Angeles (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RekruttererFase 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekruttererFase 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RekruttererFase 3
- UCLA Department of Medicine Hematologyoncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruttererFase 3
- UCLA Department of Medicine Hematologyoncology, Los Angeles
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RekruttererFase 2
- Cedars-Sinai Medical Center, Los Angeles
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- Valkyrie Clinical Trials, Los Angeles
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RekruttererFase 1/2
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RekruttererFase 3
- Valkyrie Clinical Trials /ID# 268151, Los Angeles
Kronisk lymfatisk leukemi-studier i andre byer
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN18 studier
- New York City, NY18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Chicago, IL14 studier
- Cincinnati, OH14 studier
Andre studier i Los Angeles
- Ikke-småcellet lungekreft87 studier
- Kreft (alle typer)74 studier
- Brystkreft73 studier
- Prostatakreft61 studier
- Kolorektal kreft59 studier
- Metastatisk kreft57 studier
- Eggstokkreft50 studier
- Lungekreft45 studier
- Plateepitelcancer i hode og hals42 studier
- Pankreaskreft35 studier
- Endometriekreft34 studier
- Melanom34 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.